Mayo Clinic’s new investment in Numares will accelerate the delivery of tests addressing kidney function and cardiac risk that are expected to gain U.S. Food and Drug Administration 510(k) approval early next year, according to the announcement.
WHY IT MATTERS
Using algorithms to analyze multiple biomarkers to measure disease progression in patients can help physicians improve care for those with chronic diseases, including kidney and…